{
  "paper_metadata": {
    "pmid": "30284755",
    "title": "MAIN TEXT",
    "extraction_summary": "Extracted information on TTR variants, including penetrance data and individual records."
  },
  "variants": [
    {
      "gene_symbol": "TTR",
      "cdna_notation": null,
      "protein_notation": null,
      "genomic_position": null,
      "clinical_significance": "pathogenic",
      "patients": {
        "count": 67,
        "demographics": "Not specified",
        "phenotype": "ATTRm amyloidosis"
      },
      "penetrance_data": {
        "total_carriers_observed": 67,
        "affected_count": 14,
        "unaffected_count": 53,
        "uncertain_count": null,
        "penetrance_percentage": 20.9,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "Case_1",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": null,
          "affected_status": "affected",
          "phenotype_details": "Composite endpoint occurred",
          "evidence_sentence": "Among the 67 patients with the Val30Met mutation, the composite endpoint occurred in 14 patients (21%)."
        }
      ],
      "functional_data": {
        "summary": "The Val30Met mutation is the most prevalent type of mutation in ATTRm amyloidosis in Japan.",
        "assays": []
      },
      "segregation_data": "Not specified",
      "population_frequency": "Not specified",
      "evidence_level": "Moderate",
      "source_location": "Results, paragraph 4",
      "additional_notes": "The study focused on the Val30Met mutation and its clinical outcomes.",
      "key_quotes": [
        "The Kaplan\u2013Meier analysis demonstrated a significantly higher probability of the composite endpoint in the non\u2010Val30Met group than in the Val30Met group."
      ]
    },
    {
      "gene_symbol": "TTR",
      "cdna_notation": null,
      "protein_notation": null,
      "genomic_position": null,
      "clinical_significance": "pathogenic",
      "patients": {
        "count": 23,
        "demographics": "Not specified",
        "phenotype": "Composite endpoint including all-cause death, hospitalization for heart failure, and device implantation."
      },
      "penetrance_data": {
        "total_carriers_observed": 23,
        "affected_count": 6,
        "unaffected_count": 17,
        "uncertain_count": null,
        "penetrance_percentage": 26.1,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "Case_2",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": null,
          "affected_status": "affected",
          "phenotype_details": "All-cause death",
          "evidence_sentence": "The composite endpoint occurred in 23 patients (26%): all\u2010cause death (n = 6)."
        }
      ],
      "functional_data": {
        "summary": "The study evaluated the prognosis and predictors of clinical outcomes in patients with ATTRm amyloidosis.",
        "assays": []
      },
      "segregation_data": "Not specified",
      "population_frequency": "Not specified",
      "evidence_level": "Moderate",
      "source_location": "Results, paragraph 1",
      "additional_notes": "The study highlights the clinical significance of the Val30Met mutation.",
      "key_quotes": [
        "The composite endpoint occurred in 23 patients (26%): all\u2010cause death (n = 6)."
      ]
    }
  ],
  "tables_processed": [],
  "extraction_metadata": {
    "total_variants_found": 2,
    "extraction_confidence": "high",
    "challenges": [],
    "notes": "Extracted data focused on the TTR gene variants and their penetrance."
  }
}